Keystone Law has advised French-based company Ennov as UK counsel on its acquisition of the ‘Enterprise Technology’ division of Calyx.

Ennov is a provider of the only unified compliance platform for Life Sciences. Ennov’s cloud-based solutions currently cover regulatory affairs, pharmacovigilance, quality, clinical, and document management. Calyx is a mission-critical eClinical and eRegulatory solutions provider.

The acquisition will see the creation of the ultimate cloud-based compliance platform for Life Sciences.

The transaction is expected to be completed by 31 March 2024, subject to customary closing conditions. Ennov will then integrate ‘Enterprise Technology’ into its operations while ensuring a smooth transition for clients and employees.

Keystone Law’s corporate partner Jeremy Davis led the Keystone team advising on the acquisition, which included corporate associate Sophie Welbourn, IP and commercial solicitor Rupert Casey, employment partner Emma Wayland and tax partner Paul McCourt.

Olivier Pâris, CEO of Ennov, said:

“This acquisition expands our global footprint, reinforcing our position as a key life science software industry player.

“We are extremely grateful to the team at Keystone for providing us with pragmatic and invaluable support and helping us, along with our legal advisors across the globe, to get the deal across the line.”

Jeremy Davis added:

“We were delighted to support Ennov on this hugely exciting acquisition, which will highlight the company as an industry leader for life sciences software. I look forward to seeing the Ennov team continue to expand and wish them every success.”

Ennov was also advised by Advance Capital as a Transaction Service firm and by Levine Keszler (M&A Global & France), Manatt, Phelps & Phillips (USA), S&R Associates (India), and DJS Avocats (France).



For further information please contact: